PICLIDENOSON, also known as CF-101, has the CAS number 152918-18-8. It is a potent and selective agonist of the A3 adenosine receptor, a member of the purinergic receptor family. PICLIDENOSON is an orally active pharmaceutical substance that is being investigated for its potential therapeutic applications in various inflammatory and autoimmune diseases.

The A3 adenosine receptor is primarily expressed in immune cells, and its activation has been shown to regulate immune responses. By selectively targeting this receptor, PICLIDENOSON has the potential to modulate inflammatory and immune processes without affecting other adenosine receptors in the body.

Preclinical and clinical studies have demonstrated the anti-inflammatory, immunomodulatory, and tissue-protective properties of PICLIDENOSON. It has shown promise in the treatment of conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis. The substance has also been investigated for its potential role in reducing the risk o